Prestige Consumer Healthcare Inc.’s portfolio expansion, notably with the TheraTears OTC dry eye drop brand, is Akorn Inc.’s exit from consumer health, even though its lineup still includes an OTC drug and a dietary supplement.
Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't
Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.
More from Deals
• By
Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.
• By
Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.
• By
Azelis adds dietary supplement ingredients and a large customer base across Spain to its portfolio with the acquisition of Solchem Nature.
• By
Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.